ArticleBiosensors2021
In Situ LSPR Sensing of Secreted Insulin in Organ-on-Chip.
Article in Biosensors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 45 citations in OpenAlex.
- Investigational New Drug-enabling studies in a human vessel-chip: Are we there yet?Bioengineering & translational medicine · 2026Review
- Toward continuous monitoring systems: emerging trends of on-chip sensors in organ-on-a-chip.Microsystems & nanoengineering · 2026Review
- Analyzing the Relationship between Solid-Phase Molecular Presentation and Cell Proliferation, Morphology and Secretion Using CellStudio.ACS applied materials & interfaces · 2026Article
- Integrated microoptical system for continuous fluorescence monitoring of microtissues.Microsystems & nanoengineering · 2025Article
- Spatiotemporal Interrogation of Single Spheroids Using Multiplexed Nanoplasmonic-Fluorescence Imaging.Small methods · 2025Article
- Integration of secreted signaling molecule sensing on cell monitoring platforms: a critical review.Analytical and bioanalytical chemistry · 2024Review
- Developing organs-on-chips for biomedical applications.Smart medicine · 2024Review
- Sensor-integrated brain-on-a-chip platforms: Improving the predictive validity in neurodegenerative research.Bioengineering & translational medicine · 2024Review
- Biosensor-Enhanced Organ-on-a-Chip Models for Investigating Glioblastoma Tumor Microenvironment Dynamics.Sensors (Basel, Switzerland) · 2024Review
- Insulin C-peptide secretion on-a-chip to measure the dynamics of secretion and metabolism from individual islets.Cell reports methods · 2023Article
- Muscle-on-a-chip devices: a new era for in vitro modelling of muscular dystrophies.Disease models & mechanisms · 2023Article
- Advances in microfluidic chips based on islet hormone-sensing techniques.World journal of diabetes · 2023Review
- Organs-on-Chips Platforms Are Everywhere: A Zoom on Biomedical Investigation.Bioengineering (Basel, Switzerland) · 2022Review
- Integrated biosensors for monitoring microphysiological systems.Lab on a chip · 2022Review
- Investigation of the Therapeutic Potential of New Antidiabetic Compounds Using Islet-on-a-Chip Microfluidic Model.Biosensors · 2022Article
- Islet-on-a-chip for the study of pancreatic β-cell function.In vitro models · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Organ-on-a-chip (OOC) devices offer new approaches for metabolic disease modeling and drug discovery by providing biologically relevant models of tissues and organs in vitro with a high degree of control over experimental variables for high-content screening applications. Yet, to fully exploit the potential of these platforms, there is a need to interface them with integrated non-labeled sensing modules, capable of monitoring, in situ, their biochemical response to external stimuli, such as stress or drugs. In order to meet this need, we aim here to develop an integrated technology based on coupling a localized surface plasmon resonance (LSPR) sensing module to an OOC device to monitor the insulin in situ secretion in pancreatic islets, a key physiological event that is usually perturbed in metabolic diseases such as type 2 diabetes (T2D). As a proof of concept, we developed a biomimetic islet-on-a-chip (IOC) device composed of mouse pancreatic islets hosted in a cellulose-based scaffold as a novel approach. The IOC was interfaced with a state-of-the-art on-chip LSPR sensing platform to monitor the in situ insulin secretion. The developed platform offers a powerful tool to enable the in situ response study of microtissues to external stimuli for applications such as a drug-screening platform for human models, bypassing animal testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.